PMID- 27583255
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160901
LR  - 20200929
IS  - 2306-9759 (Print)
IS  - 2313-0792 (Electronic)
IS  - 2306-9759 (Linking)
VI  - 3
DP  - 2016
TI  - Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid 
      leukemia.
PG  - 36
LID - 10.21037/sci.2016.07.08 [doi]
LID - 36
AB  - ABL tyrosine kinase inhibitors (TKIs) dramatically improves chronic myeloid 
      leukemia (CML) prognosis and most CML patients are now able to lead lives that 
      are equivalent to those of healthy individuals. However, high cost to CML 
      patients of long-term treatment and adverse effects (AEs) remain problems. At the 
      setout, a clinical study involving the discontinuation of imatinib was conducted 
      in France. Then, several stop studies of first-generation (imatinib) and 
      second-generation ABL TKIs (dasatinib, nilotinib), which induce earlier response 
      than imatinib, have also been started. These studies revealed that almost half of 
      CML patients who are treated with ABL TKIs and achieve a certain period of 
      sustained deep molecular response can stop ABL TKIs safely and obtain treatment 
      free remission (TFR). AEs of ABL TKIs withdrawal and predicting factors for 
      successful discontinuation including immunity are becoming clear gradually 
      through these studies. It is important to conduct a comprehensive examination of 
      the results of studies with a wide variety of protocols in order to determine 
      which discontinuation method results in the highest probability of TFR in 
      clinical settings.
FAU - Kimura, Shinya
AU  - Kimura S
AD  - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal 
      Medicine, Faculty of Medicine, Saga University, Saga, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160809
PL  - China
TA  - Stem Cell Investig
JT  - Stem cell investigation
JID - 101672113
PMC - PMC4981735
OTO - NOTNLM
OT  - ABL tyrosine kinase inhibitor (TKI)
OT  - chronic myeloid leukemia (CML)
OT  - discontinuation
OT  - stop
COIS- Conflicts of Interest: Shinya Kimura; Honoraria: Bristol-Myers Squibb, Pfizer, 
      Research Funding: Bristol-Myers Squibb, Novartis.
EDAT- 2016/09/02 06:00
MHDA- 2016/09/02 06:01
PMCR- 2016/08/09
CRDT- 2016/09/02 06:00
PHST- 2016/05/29 00:00 [received]
PHST- 2016/07/15 00:00 [accepted]
PHST- 2016/09/02 06:00 [entrez]
PHST- 2016/09/02 06:00 [pubmed]
PHST- 2016/09/02 06:01 [medline]
PHST- 2016/08/09 00:00 [pmc-release]
AID - sci-03-2016.07.08 [pii]
AID - 10.21037/sci.2016.07.08 [doi]
PST - epublish
SO  - Stem Cell Investig. 2016 Aug 9;3:36. doi: 10.21037/sci.2016.07.08. eCollection 
      2016.